Updated on 4 December 2012
TOT Biopharm, China, constructs first stage of its $100 mn factory in 18 months to develop anti-cancer drugs
Singapore: China's TOT Biopharm has completed 18-month project constructing the first stage of its $100 million factory complex in eastern China's Suzhou Industrial Park. The high-tech factory complex specializes in the R&D, production and marketing of anti-cancer drugs globally.
Business leaders including Wang Shaobang, deputy director of the Taiwan Affairs Office of Jiangsu Province; Yang Zhiping, director of Suzhou Industrial Park; Qianfu, chairman of Cathay United Bank's Culture and Charity Foundation; and Gao Konglian, deputy chairman of Straits Exchange Foundation attended the inauguration ceremony.
TOT Biopharm's new factory complex meets the demand for developing the bio-pharmaceutical sector set forth in China's 12th Five-Year Development Planning for Strategic Emerging Industries. The company has leveraged the rapid growth of bio-pharmaceutical technologies in China to accelerate the building of a complete bio-pharmaceutical industry chain. The company's core products include liposomal technology-based specialty medicines, biologics and innovative drugs.
The first stage of TOT Biopharm's new factory complex includes an oral anti-cancer drug plant with separate production facilities for both cytotoxics and non-cytotoxics, an injected anti-cancer drug plant and a GMP bio pilot plant with a capacity of 500 liter for cell culture, purification and filling. TOT Biopharm is set to initiate the second stage construction to expand its production scale and improve its international competitiveness.